
Renal Cell Carcinoma
Latest News

Latest Videos

CME Content
More News

The combination of nivolumab plus ipilimumab demonstrated long-term survival and response benefits as treatment of poor- to intermediate-risk patients with advanced renal cell carcinoma with sarcomatoid features compared with sunitinib, according to published results from the phase 3 CheckMate 214 clinical trial.

A supplemental New Drug Application was submitted to the FDA for cabozantinib plus nivolumab as treatment of patients with advanced renal cell carcinoma.

Frontline ilixadencel in combination with sunitinib as utilized in newly diagnosed patients with metastatic renal cell carcinoma in the phase 2 MERECA clinical trial has updated survival data, which indicates continued survival benefit with the combination over sunitinib alone.

The FDA has granted a Breakthrough Therapy designation to MK-6482, a novel HIF-2a inhibitor, as treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma who have non-metastatic tumors that measure less than 3 centimeters in size, unless immediate surgery is needed. The FDA has also granted an Orphan Drug designation to MK-6482 for the treatment of VHL disease alone.

The efficacy of nivolumab, as investigated in an interim analysis of the NORA study was confirmed as treatment of patients with advanced renal cell carcinoma who received 2 more prior lines of therapy.

Sunitinib Generates Clinical Activity After Immunotherapy Failure in Metastatic Renal Cell Carcinoma
Second-line sunitinib demonstrated clinical activity after failure on frontline immunotherapy in patients with metastatic renal cell carcinoma.




An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

Rana R. McKay, MD, discusses the phase 2 OMNIVORE trial of nivolumab and ipilimumab in patients with advanced renal cell carcinoma.

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD, discussed the findings from the phase 2 study of pembrolizumab plus lenvatinib in patients with metastatic clear cell renal cell carcinoma who have progressed on prior immune checkpoint inhibitor therapy.

If validated, the investigators believe that this non-invasive test could help detect renal cell carcinoma earlier on, thereby reducing the mortality of the disease.

A pooled analysis of phase 3 clinical trials in advanced renal cell carcinoma showed that combination immunotherapy can reduce toxicity compared with sunitinib.

Chung-Han Lee, MD, PhD, discusses the efficacy of a phase 2 study of pembrolizumab and lenvatinib in patient with metastatic clear cell renal cell carcinoma who have progressed on an immune checkpoint inhibitor.

In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, discussed findings from the analysis from the KEYNOTE-427 trial in patients with clear cell renal cell carcinoma.






























